ライフサイエンスコーパス: BLV

1 BLV alleviates liver inflammation early during treatment

2 BLV can be transmitted in cocultures to adherent suscept

3 BLV forms two domains, a plug lodged in the bile salt tr

4 BLV infection is confirmed in EAD cattle, with circulati

5 BLV infection is strongly associated with B-cell tumors

6 BLV is a retrovirus that is found worldwide in domestic

7 BLV is closely related to the human T-cell leukemia viru

8 BLV tax and pol mRNA levels increased in transwell cultu

9 BLV therapy is associated with a reappearance of TIGIT o

10 BLV viremia was assessed by spontaneous lymphocyte proli

11 BLV-treated patients with CHD (n=20) from a single-cente

12 PBMCs from 3 of 10 BLV-infected sheep displayed a lifelong deficiency in in

13 analysis of Gag sequences obtained from 125 BLV isolates from Poland, Canada, Pakistan, Kazakhstan,

14 In seropositive cows without PL (n=14), BLV-infected CD5+ and CD5- B cells accounted for 9.2% +/

15 In cows with PL (n=5), BLV-infected CD5+ and CD5- B cells accounted for 66% +/-

16 fectivity of the simple BLV derivatives in a BLV animal model.

17 tutive in vivo protein-DNA interactions in a BLV-producing cell line, Bat2Cl6.

18 Overexpression of a BLV Gag polyprotein containing a carboxy-terminal influe

19 Soon after BLV injection, immunoglobulin M+ (IgM+) and CD8+ cells i

20 e of cytotoxic T-lymphocyte response against BLV envelope proteins (Env; gp51/gp30).

21 d blood cells were cultured briefly to allow BLV expression.

22 Although BLV-seropositive dairy cattle were previously reported i

23 sults from both the compensatory mutants and BLV-HTLV chimeras indicate that the encapsidation sequen

24 a correlation between cell proliferation and BLV expression, the effect of IL-2 and IL-10 on PBMC pro

25 clonal anti-rhIL-2 antibody, as well as anti-BLV antibody, inhibited spontaneous proliferation of per

26 om PL and TB animals failed to recognize any BLV recombinant proteins.

27 ne the possibility to obtain Ca biofortified BLV by using agronomic approaches.

28 For the production of biofortified BLV, a floating system with two level of Ca (100 and 200

29 Although both BLV and HTLV-1 infection are characterised by large expa

30 Bulevirtide (BLV) is a novel and the only approved treatment option f

31 s interaction can be blocked by bulevirtide (BLV, formerly Myrcludex B), a preS1 derivative and appro

32 iferation to recombinant proteins encoded by BLV gag (p12, p15, and p24) and env (gp30, and gp51) gen

33 immune responses stimulate BLV expression by BLV-infected B cells.

34 n, these data suggest that cell infection by BLV is a multistep process requiring receptor binding (i

35 Thus, IL-10 production by BLV-infected animals with late stage disease may serve t

36 uture studies should focus on characterizing BLV infection risk factors in dairy cattle farms in the

37 ), molecular characterization of circulating BLV strains has not been undertaken.

38 irus and gag-pol or env genes of the complex BLV.

39 with late stage disease may serve to control BLV mRNA levels, while IL-2 may increase BLV mRNA in the

40 that virus neutralization by MAbs to defined BLV gp51 epitopes can occur subsequent to virus engageme

41 ed apparent bone lesion volume change (Delta BLV).

42 assessment had a significantly higher Delta BLV than those without.

43 te response may be responsible for directing BLV pathogenesis, this possibility has been left largely

44 natural killer (NK) cells before and during BLV therapy.

45 , NK cell frequencies remained stable during BLV treatment.

46 Here, we demonstrate that each BLV pre-miRNA is directly transcribed by RNAP III from i

47 inimum-energy optimal folding for the entire BLV RNA, including the previously mapped primary and sec

48 ted population of permeable cells expressing BLV and inhibited BLV replication in a culture of bovine

49 StxA1, and at various times cells expressing BLV were identified by being stained with MW1 monoclonal

50 ffects of these cytokines on BLV expression, BLV tax and pol mRNA and p24 protein were quantified by

51 This study provides structural data for BLV Gag and could be a starting point for modeling Gag-s

52 In contrast, in CD5(+) B cells from BLV-infected PL cattle, CD5 was dissociated from the BCR

53 e of peripheral blood mononuclear cells from BLV-infected sheep was expressed in COS-1 cells and test

54 Interestingly, culture of cells from BLV-negative or persistently lymphocytic cattle failed t

55 PBMC from BLV-positive animals invariably displayed spontaneous ly

56 The toxin activity in PBMC from BLV-positive cattle was selective for viral SLP and did

57 Sera from BLV-infected animals possess high BLV-neutralizing antib

58 Sera from BLV-infected animals possess high BLV-neutralizing antibody titres.

59 little viral mRNAs or proteins, exactly how BLV contributes to tumorigenesis has remained a decades-

60 Our structure reveals how BLV inhibits bile salt transport, rationalizes NTCP muta

61 er of the human T-cell leukemia virus (HTLV)/BLV group of retroviruses.

62 emia virus (BLV), another member of the HTLV/BLV genus of retroviruses, and is about fourfold lower t

63 e cis-acting elements of a virus of the HTLV/BLV group.

64 increased T-lymphocyte expression of IL-2 in BLV-infected cows contributes to development and/or main

65 Because most cells in BLV-associated tumors express little viral mRNAs or prot

66 ne lymphotropic herpesvirus as a cofactor in BLV pathogenesis is considered.

67 nonneoplastic from neoplastic conditions in BLV-infected cattle.

68 with 73 different BoLA-DRB3 alleles found in BLV-infected cattle.

69 interfilament lattice spacing is greater in BLV than in BLA and that the lattice spacing is coupled

70 MA alpha-helix II, previously implicated in BLV gRNA packaging, reduces NA binding affinity.

71 -10 inhibited BLV tax and pol mRNA levels in BLV-infected PBMCs; however, the inhibitory effect of IL

72 virus expression and disease progression in BLV infection.

73 serves as a marker of disease progression in BLV-infected cattle but is not necessarily associated wi

74 activity and may serve an important role in BLV-infected cattle by inhibiting BLV replication and th

75 rol BLV mRNA levels, while IL-2 may increase BLV mRNA in the early disease stage.

76 In contrast, IL-2 increased BLV tax and pol mRNA and p24 protein production.

77 Addition of PGE(2) increased BLV tax mRNA regardless of NS-398 addition.

78 ges secrete soluble factor(s) that increases BLV mRNA levels and that secretion of these soluble fact

79 IL-10 inhibited BLV tax and pol mRNA levels in BLV-infected PBMCs; howev

80 permeable cells expressing BLV and inhibited BLV replication in a culture of bovine peripheral blood

81 nt role in BLV-infected cattle by inhibiting BLV replication and thus slowing the progression of infe

82 the host immune system, IL-10 also inhibits BLV tax and pol mRNA levels in vitro.

83 leukemia virus (BLV) infection, we injected BLV-infected or mock-infected allogeneic cells into the

84 this work, structural models of full-length BLV Gag and Gag lacking the MA domain were generated bas

85 Our results show that full-length BLV Gag has an elongated rod-shaped structure that is re

86 hereas in type C retroviruses (lentiviruses, BLV/HTLV group) Gag is targeted efficiently to the plasm

87 uclear cells from persistently lymphocytotic BLV-infected cows, nonlymphocytotic BLV-infected cows, a

88 Previous studies have shown that both mature BLV MA and NC are able to bind to nucleic acids; however

89 ex, we generated a reporter assay to measure BLV Rex function and used it to screen a series of point

90 One BLV miRNA, BLV-miR-B4, shares partial sequence identity and shared

91 acteria have antiviral activity and mitigate BLV-induced disease.

92 horylated on serine residues, but the native BLV Env protein was not phosphorylated either in transfe

93 may serve a surveillance role during natural BLV infection.

94 Overexpression of the dominant-negative BLV Rex altered the localization of the wild-type protei

95 In contrast, the dominant-negative BLV Rex mutation had a diffuse nuclear localization and

96 uctively infected cells, indicating that new BLV infections stimulate proliferation of two different

97 ocytotic BLV-infected cows, nonlymphocytotic BLV-infected cows, and uninfected cows.

98 2-induced proliferation of PBMC from normal (BLV-negative) cows and had no effect on concanavalin A-i

99 in 53% (18 of 34) of hematologically normal, BLV-seropositive cattle and in 100% (10 of 10) of BLV-se

100 eropositive cattle and in 100% (10 of 10) of BLV-seropositive cattle with the preneoplastic syndrome

101 leukemia virus (BLV) (n = 63) and in 87% of BLV-seronegative animals (n = 38).

102 MA in the nucleic acid chaperone activity of BLV Gag.

103 2 inhibitor, NS-398, inhibited the amount of BLV mRNA detected.

104 tivity that is involved in the biogenesis of BLV miRNAs and shRNA-generated sRNAs.

105 Rare mononuclear cells acting as centers of BLV infection in culture were present within 4 to 6 days

106 aneous lymphoproliferation characteristic of BLV-induced persistent lymphocytosis is IL-2 dependent a

107 nd CD56 bright NK cells during the course of BLV treatment and inversely correlated with ALT levels i

108 This dominant-negative derivative of BLV Rex could be a useful tool to test the concept of in

109 Systemic dissemination of BLV-infected cells was thus accompanied by an increase i

110 ong with evaluating the genetic diversity of BLV strains circulating in dairy cattle in the EAD.

111 ed but did not prohibit the establishment of BLV infection in vivo.

112 Stx1A inhibited expression of BLV p24 protein by PBMC.

113 r, we identified a dominant-negative form of BLV Rex.

114 The N-terminally attached myristoyl group of BLV interacts with the lipid-exposed surface of NTCP.

115 ability clustered in the N-terminal half of BLV SU, which forms the putative receptor-binding domain

116 and IL-10 addition inhibited the increase of BLV tax and pol mRNA.

117 levels and reversed the IL-10 inhibition of BLV mRNA.

118 Using inhibition of BLV-dependent spontaneous lymphocyte proliferation as a

119 lly stimulated B cells may be a mechanism of BLV-induced PL.

120 ddress this, alanine-scanning mutagenesis of BLV PrGag was done with a virus-like particle (VLP) syst

121 ytometric analysis showed that the number of BLV-expressing cells were specifically reduced in cultur

122 ymphocytes showed sharply reduced numbers of BLV particles in StxA1-treated cultures.

123 in proliferating CD8+ cells and the onset of BLV-specific antibodies in lymph.

124 the impact of STEC on the initial phases of BLV infection in sheep.

125 low cytometry and tested for the presence of BLV by single-cell PCR.

126 e elongated structure but alters the rate of BLV Gag-facilitated annealing of two complementary nucle

127 ble to identify the nuclear export signal of BLV Rex.

128 hus, for the first time, advancing stages of BLV infection were correlated with decreased T-cell comp

129 stimulation, suggesting that stimulation of BLV tax and pol mRNA levels by PGE(2) is independent of

130 nction, we determined a cryo-EM structure of BLV-bound human NTCP.

131 n shown to be the primary cellular target of BLV, recent studies suggest that some T lymphocytes and

132 Here, we show that SU and TM of BLV do, indeed, associate through disulfide bonds, wheth

133 To gain a better understanding of BLV Rex, we generated a reporter assay to measure BLV Re

134 The inhibitory effect of IL-10 on BLV expression depends on soluble factors secreted by ma

135 To examine the effects of these cytokines on BLV expression, BLV tax and pol mRNA and p24 protein wer

136 One BLV miRNA, BLV-miR-B4, shares partial sequence identity

137 The overall BLV herd seroprevalence was 27.3% (CI: 6.03%-61.00%), me

138 followed by Sanger sequencing of the partial BLV env-gp51 gene (~ 423 bp) and phylogenetic analysis.

139 Average weight gain post-BLV challenge was higher in STEC-treated sheep than in u

140 lymphoid cell line constitutively producing BLV.

141 T lymphocytes from only AL cattle recognize BLV Env without a requirement for classical major histoc

142 The availability of the recombinant BLV receptor candidate, BLVRcp1, allowed us to determine

143 (COX-2) product of macrophages, may regulate BLV expression.

144 sociated with B-cell neoplasms that resemble BLV-associated tumors, our findings suggest a possible m

145 ts infected with the first-generation simple BLV coviruses, the second-generation replication-compete

146 Here we describe a second-generation simple BLV derivative that is encoded on a single hybrid genome

147 The first-generation simple BLV derivatives replicate as complementary viruses (covi

148 These results establish that simple BLV derivatives lacking tax and rex are infectious and i

149 immunogenicity and infectivity of the simple BLV derivatives in a BLV animal model.

150 ood mononuclear cells (PBMC), and the simple BLV derivatives were also found to infect PBMC as demons

151 Since BLV infection has serious implications for agriculture,

152 le IL-2-activated immune responses stimulate BLV expression by BLV-infected B cells.

153 Addition of PGE(2) stimulated BLV tax and pol mRNA levels and reversed the IL-10 inhib

154 In contrast, IL-2 stimulates BLV tax and pol mRNA and p24 protein expression in cultu

155 Additionally, study BLV isolates cluster under BLV-genotype 4 along with str

156 production in late disease stages suppresses BLV mRNA levels, while IL-2-activated immune responses s

157 r reverse transcription of newly synthesized BLV RNA.

158 d small RNA sequencing data demonstrate that BLV 5p miRNAs are co-terminal with 5'-triphosphorylated

159 We hypothesized that BLV treatment may influence immune cells in patients wit

160 enetic relatedness (~ 99.3-100.0%) among the BLV strains from the EAD.

161 d a full-length 64-kDa protein, but both the BLV and WRV VLPs also contained a 58-kDa protein that re

162 ect evidence for the involvement of both the BLV MA and NC domains of PrGag in viral RNA packaging.

163 blood monocytes or T lymphocytes contain the BLV provirus in seropositive cows with or without PL.

164 ombinant vaccinia virus (rVV) delivering the BLV env gene ranged from 30 to 65%.

165 ith MW1 monoclonal antibody specific for the BLV protein gp51.

166 ever, monoclonal antibodies specific for the BLV surface glycoprotein did not stain fixed PBMCs of th

167 The alteration in the BLV genome delayed but did not prohibit the establishmen

168 tingly, when conserved basic residues in the BLV MA domain of PrGag were mutated to alanine or glycin

169 s residues of the zinc finger domains in the BLV NC domain of PrGag revealed residues that led to a r

170 We modeled the BLV RBD by aligning putative structural elements with kn

171 important for Tax-mediated activation of the BLV LTR, we found footprints in regions flanking these e

172 we sought to clarify the distribution of the BLV provirus in subpopulations of peripheral blood monon

173 icate in tissue culture independently of the BLV regulatory proteins, Tax and Rex, and the RIII and G

174 Replacement of the BLV RNA region containing the primary and secondary enca

175 We show that the middle region of the BLV U3 contains multiple dual-functioning cis-acting ele

176 Limited data are available on the BLV epitopes from the core proteins recognized by CD4+ T

177 I-generated short hairpin RNAs (shRNAs), the BLV pre-miRNAs are initially 5'-triphosphorylated.

178 Thus, the BLV miRNAs avoid the conundrum of genome/mRNA cleavage b

179 A similar observation was made with the BLV PPPY motif.

180 s, both dileucine and YXXL motifs within the BLV CTM contribute to downmodulation of a protein contai

181 s but one are exposed on the surface of this BLV model.

182 suggest a possible mechanism contributing to BLV-induced tumorigenesis.

183 Cells proliferating to BLV antigens were CD4+ T lymphocytes, as shown by cell d

184 ocalization analysis revealed that wild-type BLV Rex had a punctate nuclear localization and was asso

185 Wild-type BLV typically infects peripheral blood mononuclear cells

186 plication-competent derivative, or wild-type BLV.

187 ditionally, study BLV isolates cluster under BLV-genotype 4 along with strains from Belgium, Russia a

188 Interestingly, unintegrated BLV DNA was not detected in tumor cells from cattle with

189 Thus, the presence of unintegrated BLV DNA differentiated nonneoplastic from neoplastic con

190 suggested that accumulation of unintegrated BLV DNA resulted from a process of reinfection rather th

191 The concomitant presence of unintegrated BLV DNA with viral transcriptional activity was observed

192 We have used BLV Env protein variants to gain insights into the struc

193 increase Ca content of baby leaf vegetables (BLV: basil, mizuna, tatsoi and endive), as fresh-cut pro

194 udied muscle from the bovine left ventricle (BLV), which expresses a high level of a stiff titin isof

195 lly distinct viruses, Burwash Landing virus (BLV), White River virus (WRV), and Florida virus.

196 ion structure of the bovine leukaemia virus (BLV) matrix protein by heteronuclear nuclear magnetic re

197 LV-1 and HTLV-2) and bovine leukaemia virus (BLV).

198 were seropositive for bovine leukemia virus (BLV) (n = 63) and in 87% of BLV-seronegative animals (n

199 iruses, which include bovine leukemia virus (BLV) and human T-cell leukemia virus type 1 (HTLV-1) and

200 iruses, which include bovine leukemia virus (BLV) and human T-cell leukemia virus types 1 and 2 (HTLV

201 : sheep infected with Bovine Leukemia Virus (BLV) and humans infected with Human T Lymphotropic Virus

202 Env) glycoproteins of bovine leukemia virus (BLV) and its close relative, human T-cell leukemia virus

203 irus group K (HERVK), bovine leukemia virus (BLV) and mouse mammary tumor virus (MMTV).

204 In contrast, bovine leukemia virus (BLV) expresses subgenomic RNAP III transcripts that give

205 arly establishment of bovine leukemia virus (BLV) infection, we injected BLV-infected or mock-infecte

206 arly disease stage of bovine leukemia virus (BLV) infection, while IL-10 increases in animals with a

207 ate disease stages of bovine leukemia virus (BLV) infection.

208 SU and TM proteins of bovine leukemia virus (BLV) initially were reported to be disulfide linked but

209 Bovine leukemia virus (BLV) is a complex B-lymphotrophic retrovirus of cattle a

210 Bovine leukemia virus (BLV) is a deltaretrovirus that infects domestic cattle.

211 Bovine leukemia virus (BLV) is a member of the human T-cell leukemia virus (HTL

212 The bovine leukemia virus (BLV) is an oncogenic retrovirus that is associated with

213 The Rex of bovine leukemia virus (BLV) is poorly characterized.

214 Bovine leukemia virus (BLV) is the causative agent of enzootic bovine leucosis

215 n the deltaretrovirus bovine leukemia virus (BLV) matrix (MA) and NC domains affects virus replicatio

216 oncogenic retrovirus bovine leukemia virus (BLV) produce virus when cultured briefly.

217 simple derivatives of bovine leukemia virus (BLV) that can replicate in tissue culture independently

218 e correlation between bovine leukemia virus (BLV) unintegrated DNA, viral expression, and stage of di

219 capsidation signal of bovine leukemia virus (BLV) was previously shown by deletion analysis to be dis

220 e TM protein (CTM) of bovine leukemia virus (BLV) was regulated by two membrane-proximal dileucine mo

221 Bovine leukemia virus (BLV), a retrovirus related to human T-cell leukemia viru

222 demonstrate that the bovine leukemia virus (BLV), a retrovirus with an RNA genome, encodes a conserv

223 Bovine leukemia virus (BLV), a transactivating lymphotropic retrovirus, is the

224 comparable to that of bovine leukemia virus (BLV), another member of the HTLV/BLV genus of retrovirus

225 in (Stx) acts against bovine leukemia virus (BLV)-expressing cells was obtained.

226 Bovine leukemia virus (BLV)-induced persistent lymphocytosis is characterized b

227 Stx activity against bovine leukemia virus (BLV)-infected cells in vitro and hypothesized that STEC

228 cattle caused by the bovine leukemia virus (BLV).

229 has activity against bovine leukemia virus (BLV).

230 assembly pathway for bovine leukemia virus (BLV).

231 om cows infected with bovine leukemia virus (BLV).

232 cattle infected with bovine leukemia virus (BLV; a retrovirus closely related to human T-cell leukem

233 lustering, we found that, for HLA-I, viruses BLV, JCV and MMTV were grouped with the BC-HLA, whereas,

234 ith the BC-HLA, whereas, for HLA-II, viruses BLV, HERVK, HPV, JCV, and MMTV were grouped with BC-HLA.

235 not detected in tumor cells from cattle with BLV-associated lymphocytic leukemia/malignant lymphoma d

236 ne sera from animals naturally infected with BLV blocked gp51 binding to recombinant BLVRcp1.

237 determined in cattle naturally infected with BLV.

238 l blood that are significantly infected with BLV.

239 ing that both reagents likely interfere with BLV-dependent initiation of SLP.

240 be useful tools in comparative studies with BLV to evaluate the role of tax and rex in maintenance o

241 ons of human CD8-alpha plus a wild-type (wt) BLV CTM was detectable on the surface of only 40% of the